A planning device generating control data for a treatment apparatus for refraction-correcting ophthalmic surgery is provided, said apparatus using a laser device to separate a corneal volume, which is to be removed for correction, from the surrounding cornea by at least one cut surface in the cornea of an eye, said planning device comprising an interface for receiving corneal data including information on pre-operative cuts which were generated in a previous ophthalmic operation, and computing means for defining a corneal cut surface which confines the corneal volume to be removed, said computing means defining the corneal cut surface on the basis of the corneal data and generating a control dataset for the corneal cut surface for control of the laser device.

An ocular implant is provided. In some embodiments, the ocular implant includes a body that is curved about a longitudinal central axis and a distal body portion that defines a longitudinal channel including a channel opening. The implant is sized and configured such that the ocular implant assumes an orientation in which the channel opening is adjacent a major side of Schlemm's canal when the ocular implant is disposed in Schlemm's canal. Methods for delivering ocular implants into Schlemm's canal are also provided. Some methods include covering openings in the ocular implant, advancing the implant into Schlemm's canal while at least some of the openings are covered, and uncovering the openings while the distal portion of the implant is disposed in Schlemm's canal.

A device for delivering a treatment medium to an eye includes a first body portion configured to be removably inserted and secured in an opening of the eye, and a second body portion supported by the first body portion. At least the second body portion includes a treatment medium, and a coating having an opening through which the treatment medium elutes out of the device.

Devices, methods, and kits for ocular drug delivery are described herein. An apparatus can include a housing, an energy storage member, a barrel, and a hub. The housing contains the energy storage member. A proximal end portion of the barrel is coupled to a distal end portion of the housing. The barrel is configured to contain medicament and includes at least a portion of a piston and an elastomeric member. The piston is configured to move the elastomeric member within the barrel in response to a force produced by the energy storage member. The hub is coupled to a distal end portion of the barrel. An inner surface of the hub defines a nozzle through which the medicament flows when the elastomeric member moves within the barrel. The nozzle and the energy storage member are collectively configured to produce a fluid jet to access a target location within an eye.

Apparatus and methods for medicament delivery. The apparatus may include, and the methods may involve, a delivery device for delivering a target amount of the medicament from a distal end of the device. The device may include a rod for moving a plunger that discharges the medicament from the distal end. The device may avoid or reduce deformation of the plunger during the discharge. The plunger motion may be stopped by detent that interacts with the rod. The apparatus and the methods may provide an operator indication of progress of stages of operation. The device may feature triggers corresponding to stages of medicament displacement from the device, such as pre-delivery stages, including priming.

The invention relates to a device for dosing liquid from a liquid-receiving element (2), in which the liquid-receiving element (2) comprises an outlet valve (1), and a dosing system is available, said dosing system consisting of a first actuating wing (4) and a second actuating wing (5), which are arranged around the liquid-receiving element (2) and can be moved in relation to each other such that they compress the liquid-receiving element (2), a mechanical dosing stop being available.

The subject matter of the invention is a storage container with a removable cover for pipettes containing a fluid, in particular a treatment fluid for eyes, wherein at least one pipette is hold in the cover, as well as a set consisting of the storage container and at least one pipette.

A microfluidic flow restrictor that uses micron-sized beads to impede flow is described. The flow rate can be adjusted by adding or removing the beads using injection needles through self-sealing ports, one injection needle injecting or aspirating beads and another injection needle pushing or pulling fluid from outside of a bead trap within the flow restrictor. In alternative embodiments, the beads or other filler material can be trapped in a manifold bead trap such that they block a subset of fluid channels of the flow restrictor, allowing fluid to flow freely through the rest of the fluid channels. The flow restrictor can be integrated with a contact lens or implantable medical device for use in dispensing liquid therapeutic agents at flow rates of microliters per minute or moving body fluids at a controlled rate from one part of the body to another.

The present invention relates to a system for corneal crosslinking of injured corneas, treating keratoconus, or correcting vision, the system comprising: a hyaluronic acid-dye conjugate; and a contact lens including an LED light source.

In the present invention, a dye is activated by receiving light irradiated from the LED light source of the contact lens so as to generate radicals, thereby generating a covalent bond between amino acid radicals of corneal collagen, and strengthening a collagen layer. In the present invention, the hyaluronic acid-dye conjugate, in which hyaluronic acid is bound to the dye, is used to improve penetration of the dye in the cornea, and the contact lens is used together with the hyaluronic acid-dye conjugate to further improve the penetration of the dye. In addition, the structure of the lens which presses the center of the cornea deforms the shape of the cornea, thereby having a vision correction effect.

Methods, systems, and compositions for maintaining functioning drainage blebs to reduce intraocular pressure (IOP) of an eye being treated for glaucoma. The methods, systems, and compositions feature the combination of a minimally invasive glaucoma surgery (MIGS) implant or procedure and the application of beta radiation to the bleb. The beta radiation can function to inhibit or reduce the inflammation and/or fibrogenesis that typically occurs after insertion of a MIGS implant and leads to bleb failure. By reducing inflammation and/or fibrogenesis, the MIGS implant and the blebs can remain functioning appropriately.